RE:RE:RE:Any comments? Why are down in this sector? Funny trading...
- Fund managed position at $1.65 in February 2021.
- Share price tanks 70% from February 2021 placement to date.
- ACB files patent infringement July 21. The patent relates to the aromatic prenyl transferase CsPT1 from cannabis.
- March 2020 Pete Michels, Head of Global Fermentation, AMRI states, “We’re excited about Willow’s unique technical capabilities – including their execution of plant gene discovery and rapid strain engineering – to maximize the options for successfully delivering new, commercially-relevant fermentation processes.”
- Willow Quotes: "Willow has developed a proprietary cannabinoid biosynthetic pathway for producing ultra-pure cannabinoids that does not involve CsPT1".
If Pete Michels comments that Willow is pursuing unique plant gene discoveries/engineering and Willow also states that their proprietary cannabinoid biosynthetic pathway process does not involve CsPT1 - then what is the point of the claim alleging patent infringement? Is this just to scare everyone out of their positions?
When you synthesize the "mother of all cannabinoids (CBG)" via proprietary gene discoveries and unique synthetic methods, all other cannabinoids will follow this proprietary system.
Proprietary -
owned and
legally controlled by a
particular company.
At 53c the market is valuing the company at a m/c without any progress on their cannabinoid developments nor the commercialization strategies now 10 months further advanced?
What about their EV ratio at 53c - too low even with a high cash burn rate (despite potential sales revenue coming in - however small).
It is all very quiet on the pilot ready pipeline expectations;
- THC/THCA
- CBD/CBDA
- CBN/CBNA
- CBGV/CBGVA
- THCV/THCVA
- CBDV/CBDVA
Trade Safe.